In August 2022, President Biden signed the Inflation Reduction Act (IRA) into law. The sprawling legislation includes a number of Democratic signature initiatives, including several provisions impacting Medicare drug pricing and affordability. Provisions of the law go into effect incrementally over several years, but the Centers for Medicare and Medicaid Services (CMS) has begun the process of negotiating the prices for the first ten drugs to qualify under the IRA. The IRA reforms have major implications for the future of Medicare drug coverage, particularly for individuals who depend on high-cost drugs. Read our latest issue of Health Care in Motion to learn more.